Esketamine Nasal Spray Market

1. Analysis of Esketamine Nasal Spray Market Size by Research Nester Reveals the Market to Grow with a CAGR of ~7% during 2024-2036 and Attain ~USD 8 Billion by 2036 Research Nester assesses the growth and market size of global esketamine nasal spray market which is anticipated to be on account of the increasing demand from end-use industries and increasing demand for healthcare sector. New York – October 11, 2023 - Research Nester’s recent market research analysis on “Esketamine Nasal Spray Market: Global Demand Analysis & Opportunity Outlook 2036” delivers a detailed competitors analysis and a detailed overview of the global esketamine nasal spray market in terms of market segmentation by type, end user, and by region. Increasing Mental Health Awareness to Promote Global Market Share of Esketamine Nasal Spray Growing awareness of mental health issues has reduced stigma and encouraged more individuals to seek treatment. Esketamine's market has benefited from this trend, as patients and healthcare providers explore new options to manage depression. The World Mental Health Day 2021, organized by WHO, emphasized the importance of mental health awareness and care, signaling a global commitment to address mental health issues.

2. Request Free Sample Copy of this Report @ https://www.researchnester.com/sample-request-5318 Some of the major growth factors and challenges that are associated with the growth of the global esketamine nasal spray market are: Growth Drivers: • Increasing Investments in Healthcare • Growing Onset of Action Challenges: Esketamine administration must occur in a healthcare setting under the supervision of a qualified healthcare professional. This requirement can be logistically challenging for both patients and healthcare providers. The need for monitoring after administration, including observation for potential side effects, adds to the complexity of treatment and may limit its accessibility. Request for customization @ https://www.researchnester.com/customized-reports-5318 The major depressive disorder segment is to garner a highest revenue by the end of 2036 by growing at a significant CAGR over the forecast period. Esketamine's approval for MDD with suicidal ideation addresses a critical need. This growth driver is grounded in the potential to save lives. Esketamine provides a treatment option that not only targets MDD but also reduces the associated suicide risk, which is a major concern in this patient population. MDD is a significant risk factor for suicide, with a substantially higher prevalence among those who have attempted suicide or died by suicide.

3. By region, the Europe esketamine nasal spray market is to generate a notable revenue by the end of 2036. Europe has a significant burden of depression, with millions of individuals affected by this mental health condition. Furthermore, a substantial portion of these individuals may experience treatment-resistant depression (TRD), where conventional treatments have been ineffective. The high prevalence of depression, along with the prevalence of TRD, creates a robust demand for innovative treatments like Esketamine. It offers an alternative for those who have not responded adequately to existing therapies. Many European countries have adopted progressive mental health policies, with an emphasis on reducing stigma and improving access to mental health care. These policies prioritize early intervention and innovative treatments. Progressive mental health policies promote awareness, reduce stigma, and encourage the adoption of novel treatments like Esketamine. They create an environment that fosters the integration of Esketamine into the mental health treatment landscape. Consult our expert analysts at: info@researchnester.com or contact us at: https://www.researchnester.com/contact for any customized report. This report also provides the existing competitive scenario of some of the key players of the global esketamine nasal spray market which includes company profiling of Janssen Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Allergan, Inc. (now part of AbbVie), H. Lundbeck A/S, Johnson & Johnson, Mylan N.V.,and others. Access our detailed report at: https://www.researchnester.com/reports/esketamine-nasal- spray-market/5318

4. Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties. Contact for more Info: AJ Daniel Email: info@researchnester.com U.S. Phone: +1 646 586 9123 U.K. Phone: +44 203 608 5919